| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Nicolas M Furiak, Haya Ascher-Svanum, Robert W Klein, Lee J Smolen, Anthony H Lawson, Robert R Conley, Steven D Culle. Cost-effectiveness model comparing olanzapine and other oral atypical antipsychotics in the treatment of schizophrenia in the United States. Cost effectiveness and resource allocation : C/E. vol 7. 2010-05-20. PMID:19351408. |
this study compares the cost-effectiveness of oral olanzapine, oral risperidone (at generic cost, primary comparator), quetiapine, ziprasidone, and aripiprazole in the treatment of patients with schizophrenia from the perspective of third-party payers in the u.s. health care system. |
2010-05-20 |
2023-08-12 |
Not clear |
| Adelaide S Robb, William H Carson, Margaretta Nyilas, Mirza Ali, Robert A Forbes, Taro Iwamoto, Sheila Assunção-Talbott, Richard Whitehead, Andrei Pikalo. Changes in positive and negative syndrome scale-derived hostility factor in adolescents with schizophrenia treated with aripiprazole: post hoc analysis of randomized clinical trial data. Journal of child and adolescent psychopharmacology. vol 20. issue 1. 2010-05-19. PMID:20166794. |
changes in positive and negative syndrome scale-derived hostility factor in adolescents with schizophrenia treated with aripiprazole: post hoc analysis of randomized clinical trial data. |
2010-05-19 |
2023-08-12 |
Not clear |
| Adelaide S Robb, William H Carson, Margaretta Nyilas, Mirza Ali, Robert A Forbes, Taro Iwamoto, Sheila Assunção-Talbott, Richard Whitehead, Andrei Pikalo. Changes in positive and negative syndrome scale-derived hostility factor in adolescents with schizophrenia treated with aripiprazole: post hoc analysis of randomized clinical trial data. Journal of child and adolescent psychopharmacology. vol 20. issue 1. 2010-05-19. PMID:20166794. |
this post hoc analysis evaluated the effects of aripiprazole on positive and negative syndrome scale (panss) hostility factor scores in adolescents with schizophrenia. |
2010-05-19 |
2023-08-12 |
Not clear |
| Emmanuel Stip, Valérie Tourjma. Aripiprazole in schizophrenia and schizoaffective disorder: A review. Clinical therapeutics. vol 32 Suppl 1. 2010-05-12. PMID:20152550. |
aripiprazole in schizophrenia and schizoaffective disorder: a review. |
2010-05-12 |
2023-08-12 |
Not clear |
| Emmanuel Stip, Valérie Tourjma. Aripiprazole in schizophrenia and schizoaffective disorder: A review. Clinical therapeutics. vol 32 Suppl 1. 2010-05-12. PMID:20152550. |
aripiprazole is an atypical antipsychotic that has been found to improve positive and negative symptoms of schizophrenia with a favorable adverse-effect profile. |
2010-05-12 |
2023-08-12 |
Not clear |
| Chi-Un Pae, Alberto Chiesa, Laura Mandelli, Ashwin A Patkar, Sara Gibiino, Alessandro Serrett. Predictors of early worsening after switch to aripiprazole: a randomized, controlled, open-label study. Clinical drug investigation. vol 30. issue 3. 2010-05-11. PMID:20155991. |
in a previous study, we compared different options for switching to aripiprazole and found that patients with schizophrenia switched to aripiprazole with immediate discontinuation of the previous antipsychotic showed an increase in symptom severity after 1 week. |
2010-05-11 |
2023-08-12 |
Not clear |
| Pilar Lopez-Garcia, Carlos Chiclana, Rafael Gonzale. Combined use of ECT with aripiprazole. The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry. vol 10. issue 4 Pt 3. 2010-03-19. PMID:17853257. |
this case report is on the combined use of electroconvulsive treatment (ect) with a partial dopamine agonist, aripiprazole, in the treatment of a 30-year-old man with chronic and refractory paranoid schizophrenia. |
2010-03-19 |
2023-08-12 |
Not clear |
| Chi-Un Pa. A review of the safety and tolerability of aripiprazole. Expert opinion on drug safety. vol 8. issue 3. 2010-03-02. PMID:19505266. |
it seems that the efficacy of aripiprazole for treating schizophrenia is mediated through a combination of partial agonism at dopamine d2 and serotonin 5-ht1a receptors and antagonism at serotonin 5-ht2a receptors. |
2010-03-02 |
2023-08-12 |
Not clear |
| Leslie Citrom. Using oral ziprasidone effectively: the food effect and dose-response. Advances in therapy. vol 26. issue 8. 2010-03-01. PMID:19669631. |
comparisons with other second-generation antipsychotics in meta-analyses reveal similar efficacy to that observed for quetiapine or aripiprazole, but inferior efficacy to that of olanzapine or risperidone in the treatment of schizophrenia. |
2010-03-01 |
2023-08-12 |
Not clear |
| M Han, X F Huang, T M du Bois, C Den. The effects of antipsychotic drugs administration on 5-HT1A receptor expression in the limbic system of the rat brain. Neuroscience. vol 164. issue 4. 2010-02-19. PMID:19778583. |
the results indicate that aripiprazole and olanzapine have differential effects on 5-ht1a receptor expression, which may contribute to their distinct profiles in improving negative symptoms and cognitive deficits in schizophrenia. |
2010-02-19 |
2023-08-12 |
rat |
| Shikma Keller, Heinz Drexler, Pesach Lichtenber. Very high-dose clozapine and electroconvulsive therapy combination treatment in a patient with schizophrenia. The journal of ECT. vol 25. issue 4. 2010-02-17. PMID:19440159. |
we report here the case of a 19-year-old man with paranoid schizophrenia who responded only partially to treatment with daily doses of clozapine, 1800 mg; aripiprazole, 20 mg; and clonazepam, 6 mg. we reduced the clozapine to 1600 to 1700 mg, maintaining therapeutic serum levels, and added a course of electroconvulsive therapy that included 24 treatments. |
2010-02-17 |
2023-08-12 |
Not clear |
| Katja Komossa, Christine Rummel-Kluge, Franziska Schmid, Heike Hunger, Sandra Schwarz, Hany George G El-Sayeh, Werner Kissling, Stefan Leuch. Aripiprazole versus other atypical antipsychotics for schizophrenia. The Cochrane database of systematic reviews. issue 4. 2010-01-27. PMID:19821375. |
aripiprazole versus other atypical antipsychotics for schizophrenia. |
2010-01-27 |
2023-08-12 |
Not clear |
| Bart Peters, Lieuwe de Haa. Remission of schizophrenia psychosis and strong reduction of obsessive-compulsive disorder after adding clozapine to aripiprazole. Progress in neuro-psychopharmacology & biological psychiatry. vol 33. issue 8. 2010-01-25. PMID:19766686. |
remission of schizophrenia psychosis and strong reduction of obsessive-compulsive disorder after adding clozapine to aripiprazole. |
2010-01-25 |
2023-08-12 |
Not clear |
| Akifumi Nakamura, Kazuo Mihara, Goyo Nagai, Takeshi Suzuki, Tsuyoshi Kond. Pharmacokinetic and pharmacodynamic interactions between carbamazepine and aripiprazole in patients with schizophrenia. Therapeutic drug monitoring. vol 31. issue 5. 2010-01-18. PMID:19701114. |
pharmacokinetic and pharmacodynamic interactions between carbamazepine and aripiprazole in patients with schizophrenia. |
2010-01-18 |
2023-08-12 |
Not clear |
| Akifumi Nakamura, Kazuo Mihara, Goyo Nagai, Takeshi Suzuki, Tsuyoshi Kond. Pharmacokinetic and pharmacodynamic interactions between carbamazepine and aripiprazole in patients with schizophrenia. Therapeutic drug monitoring. vol 31. issue 5. 2010-01-18. PMID:19701114. |
pharmacokinetic and pharmacodynamic interactions between carbamazepine and aripiprazole were studied in 18 inpatients with schizophrenia being treated with aripiprazole. |
2010-01-18 |
2023-08-12 |
Not clear |
| Akifumi Nakamura, Kazuo Mihara, Goyo Nagai, Takeshi Suzuki, Tsuyoshi Kond. Pharmacokinetic and pharmacodynamic interactions between carbamazepine and aripiprazole in patients with schizophrenia. Therapeutic drug monitoring. vol 31. issue 5. 2010-01-18. PMID:19701114. |
the present study implies that carbamazepine augmentation may be effective for patients with schizophrenia treated with aripiprazole, although carbamazepine dramatically decreases plasma concentrations of aripiprazole and dehydroaripiprazole, by inducing the metabolism of these compounds. |
2010-01-18 |
2023-08-12 |
Not clear |
| Aripiprazole and adolescent schizophrenia: a simple neuroleptic. No comparison with standard neuroleptic in adolescents. Prescrire international. vol 18. issue 104. 2010-01-12. PMID:20025091. |
aripiprazole and adolescent schizophrenia: a simple neuroleptic. |
2010-01-12 |
2023-08-12 |
Not clear |
| John M Kane, Edward Kim, Hong J Kan, Zhenchao Guo, John A Bates, Richard Whitehead, Andrei Pikalo. Comparative utility of aripiprazole and haloperidol in schizophrenia: post hoc analysis of two 52-week, randomized, controlled trials. Applied health economics and health policy. vol 7. issue 2. 2009-12-11. PMID:19731968. |
comparative utility of aripiprazole and haloperidol in schizophrenia: post hoc analysis of two 52-week, randomized, controlled trials. |
2009-12-11 |
2023-08-12 |
Not clear |
| Takayuki Ishida, Yoshihito Obara, Chiaki Kame. Effects of some antipsychotics and a benzodiazepine hypnotic on the sleep-wake pattern in an animal model of schizophrenia. Journal of pharmacological sciences. vol 111. issue 1. 2009-11-25. PMID:19721330. |
in addition, aripiprazole showed a sleep-inducing effect in schizophrenia model rat. |
2009-11-25 |
2023-08-12 |
rat |
| John M Kane, Christoph U Correll, Donald C Goff, Brian Kirkpatrick, Stephen R Marder, Estelle Vester-Blokland, Wei Sun, William H Carson, Andrei Pikalov, Sheila Assunção-Talbot. A multicenter, randomized, double-blind, placebo-controlled, 16-week study of adjunctive aripiprazole for schizophrenia or schizoaffective disorder inadequately treated with quetiapine or risperidone monotherapy. The Journal of clinical psychiatry. vol 70. issue 10. 2009-11-23. PMID:19906340. |
a multicenter, randomized, double-blind, placebo-controlled, 16-week study of adjunctive aripiprazole for schizophrenia or schizoaffective disorder inadequately treated with quetiapine or risperidone monotherapy. |
2009-11-23 |
2023-08-12 |
Not clear |